BTC Capital Management Inc. Purchases 4,344 Shares of Sanofi (NYSE:SNY)
BTC Capital Management Inc. boosted its position in Sanofi (NYSE:SNY) by 41.1% during the second quarter, Holdings Channel reports. The firm owned 14,910 shares of the company’s stock after buying an additional 4,344 shares during the period. BTC Capital Management Inc.’s holdings in Sanofi were worth $714,000 at the end of the most recent quarter.
Other large investors have also recently added to or reduced their stakes in the company. Fisher Asset Management LLC increased its stake in Sanofi by 8.1% in the second quarter. Fisher Asset Management LLC now owns 13,638,458 shares of the company’s stock worth $653,419,000 after buying an additional 1,022,953 shares during the period. Bank of America Corp DE increased its stake in Sanofi by 8.2% in the first quarter. Bank of America Corp DE now owns 7,531,334 shares of the company’s stock worth $340,792,000 after buying an additional 572,652 shares during the period. Wells Fargo & Company MN increased its stake in Sanofi by 22.2% in the first quarter. Wells Fargo & Company MN now owns 4,492,719 shares of the company’s stock worth $203,296,000 after buying an additional 815,820 shares during the period. Brandes Investment Partners LP increased its stake in Sanofi by 3.0% in the first quarter. Brandes Investment Partners LP now owns 3,490,226 shares of the company’s stock worth $157,933,000 after buying an additional 102,511 shares during the period. Finally, Hamlin Capital Management LLC increased its stake in Sanofi by 11.8% in the first quarter. Hamlin Capital Management LLC now owns 1,768,523 shares of the company’s stock worth $80,026,000 after buying an additional 186,280 shares during the period. 9.96% of the stock is currently owned by institutional investors and hedge funds.
Shares of Sanofi (NYSE SNY) opened at 47.55 on Friday. The firm’s 50-day moving average price is $47.99 and its 200-day moving average price is $46.11. Sanofi has a 12-month low of $36.81 and a 12-month high of $50.24. The firm has a market capitalization of $119.42 billion, a P/E ratio of 11.23 and a beta of 0.88.
Sanofi (NYSE:SNY) last announced its earnings results on Monday, July 31st. The company reported $0.74 earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of $0.74. Sanofi had a net margin of 25.89% and a return on equity of 25.34%. The firm had revenue of $8.66 billion for the quarter, compared to analyst estimates of $8.71 billion. The company’s revenue was down 2.3% on a year-over-year basis. Equities analysts predict that Sanofi will post $3.26 earnings per share for the current fiscal year.
A number of equities research analysts recently weighed in on SNY shares. BidaskClub downgraded Sanofi from a “buy” rating to a “hold” rating in a research report on Friday, June 9th. Zacks Investment Research raised Sanofi from a “hold” rating to a “buy” rating and set a $55.00 target price on the stock in a research report on Friday, June 2nd. J P Morgan Chase & Co reissued a “neutral” rating on shares of Sanofi in a research report on Thursday, April 20th. Berenberg Bank downgraded Sanofi from a “buy” rating to a “hold” rating in a research report on Thursday, May 11th. Finally, TheStreet raised Sanofi from a “c+” rating to a “b-” rating in a research report on Monday, April 24th. Two equities research analysts have rated the stock with a sell rating, nine have given a hold rating and five have issued a buy rating to the company. Sanofi presently has an average rating of “Hold” and an average target price of $63.75.
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi (NYSE:SNY).
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.